Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

JJDC buys $33mm in Bavarian Nordic equity

Executive Summary

Johnson & Johnson's Johnson & Johnson Development Corp. purchased $32.8mm (DKK207.5mm) new Bavarian Nordic AS stock in a private placement of 512,102 shares priced at $64.18. As a result, JJDC now holds 1,844,086 shares in Bavarian Nordic corresponding to 5.77% of the share capital and voting rights. The financing is part of a concurrent deal between Bavarian Nordic and J&J's Janssen Pharmaceuticals Inc. subsidiary in which Janssen received exclusive global rights to use MVA-BN technology to develop vaccines for hepatitis B virus and HIV.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies